one of R11, R12, R13 and R14 is —NR₃COR₃₁, —NR₃CONR₃R₃₁, —NR₃SO₂R₃₁, —CO₂R₃, —CO₂H, —C_0-8alkylNR₃R₃₁ or —CONR₃R₃R₃₁; and the others are each independently F, Cl, Co_0-3alkyl, C_0-8alkoxy, or —N(C_0-8alkyl)(C_0-8alkyl);

X is phenyl, optionaily substituted with 1-4 of halogen, —NR₃₂R₃₃, —NR₃₂COR₃₃, —NR₃₂CO2R₃₃, —NR₃₂SO₂R₃₃, —OR₃₂, SR₃₂, —SO₂R₃₂, —SO₂NR₃₂R₃₃, —CO₂R₃₂, —CO₂H, —CONR₃₂R₃₃, —C_0-8alkyl, —C_2-8alkenyl, —C_2-8alkynyl, —CN, CF₃, OCF₃, NO₂, or oxo;

Y is

wherein the point of attachment to X can be from either the left or the right as shown;

R_a and R_b, are each independently C_0-8alkyl or C_3-8cycloallcyl; or R_a and R_b, taken together with the C to which they are attached form a saturated or partially unsaturated 3-10 membered ring;

n is 1, 2, 3, 4 or 5;

Z is phenyl, optionally substituted with 1-5 independent halogen, —NR₃₄R₃₅, —NR₃₄COR₃₅, —NR₃₄C(O)OR₃₅, —NR₃₄SO₂R₃₅, —OR₃₄, —SR₃₄, —SO₂R₃₄, —SO₂NR₃₄R₃₅, —C(O)OR₃₄, —CO₂H, —CONR₃₄R₃₅, C_0-8alkyl, C_2-8alkenyl, C_2-8alkynyl, —OC_0-8alkyl, —SC_0-8alkyl, —SO₂C_0-8alkyl, —SO₂N(C_0-8alkyl)(C_0-8alkyl), —C(O)OC_0-8alkyl, CN, CF₃, NO₂, oxo, carbocyclyl, C_0-8alkyl-O—C_0-8alkyl, C_0-8alkyl-O—C(O)—C_0-8alkyl, or C_0-8alkyl-C(O)-O—C_0-8alkyl;

R₃, R₃₄ , and R₃₅ are independently —CF₃, —CHF₂, —C_0-8alkyl-O—C_0-8alkyl, —C_0-8alkyl-N(C_0-8alkyl)(C_0-8alkyl), —C_0-8alkyl-S(O)_0-2—C_0-8alkyl, —C_0-8alkyl-S(O)₂N(C_0-8alkyl)(C_0-8alkyl), or C_0-8alkyl optionally substituted with OH;

R₃₁ is C_0-8alkyl substituted by morpholinyl;

R₃₂ and R₃₃ are independently —CF₃, —CHF₂, —C_0-8alkyl-O—C_0-8alkyl, C_0-8alkyl-N(C_0-8alkyl)(C_0-8alkyl), C_0-8alkyl-S(O)_0-2—C_0-8alkyl, or —C_0-8alkyl-S(O)₂N(C_0-8alkyl)(C_0-8alkyl);

provided that when Y is —OCH₂—, Z must be substituted with 1-5 —NR₃₄R₃₅, —NR₃₄COR₃₅, —NR,₃₄C(O)OR₃₅, —NR₃₄SO₂R₃₅, —OR₃₄, —SR₃₄, —SO₂R₃₄, —SO₂NR₃₄R₃₅, —CO₂R₃₄, —CO₂H, —CONR₃₄ R₃₅, C_0-8alkyl, C_2-8alkenyl, C_2-8alkynyl, CF₃, NO₂, oxo, or carbocyclyl substituents optionally substituted with OH;

or a pharmaceutically acceptable salt or N-oxide thereof.